Nanocarrier-based systems for targeted and site specific therapeutic delivery

Purpose: Conventional systemic drug administration suffers from low site-specific bioavailability, unfavorable biodistribution, poor target accumulation, and adverse side effects. There is a need for carrier-based systems that enable localized and targeted delivery, improve therapeutic efficacy, and reduce toxicity.

Hypothesis: No formal experimental hypothesis. Central thesis: nanocarriers, supramolecular gels, and live cell-based carriers can be engineered for passive or active targeting to achieve site-specific therapeutic delivery, improving treatment efficacy while limiting off-target effects.

Aims: Review advances in carrier-based targeted and localized drug delivery systems. - Focus on nanocarriers (polymeric, lipid, inorganic), supramolecular gels, and live cell-based delivery. - Summarize targeting strategies and ligands, especially for cancer cells. - Provide perspectives on future directions and clinical translation challenges.

Delivery system: Polymeric nanoparticles and dendrimers: PLGA, PACA, PCL, polyanhydrides, PEI, chitosan, gelatin, PAMAM, PPI; payloads include anticancer drugs (cisplatin, paclitaxel, doxorubicin), siRNA, DNA, imaging agents. - Solid lipid nanoparticles (SLNs): natural/synthetic lipids; dual-targeted DOX/SPION SLNs with folate/dextran layer-by-layer coating for colon cancer. - Liposomes: neutral, PEGylated, cationic, ligand-modified; marketed examples: DaunoXome, Myocet, Doxil, DepoCyt, Caelyx, Marqibo, Lipoplatin. - Nanostructured lipid carriers (NLCs): biodegradable lipid matrix; LHRH-targeted NLCs for inhalation co-delivery of anticancer drugs and siRNA; PEGylated NLCs for topical, pulmonary, ocular delivery. - Mesoporous silica nanoparticles (MSNs): MSNs@PDA-PEG-FA for pH-stimulated DOX release; MSNs-TAT and MSNs-RGD/TAT for nuclear and sequential targeting. - Gold and iron-oxide nanoparticles: gold NPs for drug/gene delivery and imaging; SPIONs for MRI, magnetic hyperthermia, and magnetic targeting. - Supramolecular gels: hydrogels, organogels, metallogels; self-delivery systems using drug-derived gelators (e.g., taxol-tetrapeptide, paclitaxel-folate-tyrosine phosphate, NSAID-peptide conjugates). - Live cell-based systems: red blood cells, mesenchymal stem cells, neural stem cells, immune cells; surface conjugation of drugs or nanoparticles via avidin-biotin, maleimide-thiol, or phagocytosis. - Targeting ligands: folate, LHRH, RGD, TAT, antibodies, peptides, salbutamol, mannose, etc. - Payloads: small-molecule drugs, siRNA, antisense oligonucleotides, plasmid DNA, imaging agents, cytokines, nucleic acids.

Approach: Review of in vitro and in vivo literature. Disease models include cancer (lung, colon, melanoma, ovarian, breast, prostate), idiopathic pulmonary fibrosis, cystic fibrosis, skin inflammation/allergy, Alzheimer’s disease, and bacterial infection. Cell lines include A549, HeLa, A2780, A2780cis, A2780cp, MDA-MB-231, RAW 264.7, and others. Animal models include mice and rats, with orthotopic lung cancer, colon tumor, melanoma, and fibrosis models. Clinical examples include marketed liposomal products and clinical trials.

Key methods: Particle characterization: size, zeta potential, TEM/SEM, DLS, drug loading, release kinetics. - Cellular assays: MTT, IC50, cellular uptake, gene expression (qPCR, Western), knockdown efficiency. - In vivo: tumor volume, survival, biodistribution, imaging (IVIS, MRI, CT), histology, apoptosis. - Gel characterization: self-assembly, rheology, biocompatibility, anti-inflammatory activity (PGE2 assay), antibacterial activity. - Live cell systems: surface conjugation efficiency, cell viability, migration, tumor tropism.

Key results: Dual-targeted DOX/SPION SLNs enhanced accumulation at colon tumor sites and effectively inhibited orthotopic colon tumor in mice after oral administration. - Liposomal DOX plus MRP1/BCL2 siRNA by inhalation showed high anticancer efficiency and low adverse effects on healthy organs in an orthotopic human lung carcinoma model. - NLCs co-delivering paclitaxel and siRNA targeting MRP1/BCL2 by inhalation significantly inhibited lung tumor growth; tumor volume was reduced compared with intravenous paclitaxel. - NLC-PGE2 plus three siRNAs (MMP3, CCL12, HIF1A) substantially improved survival of mice with idiopathic pulmonary fibrosis. - MSNs@PDA-PEG-FA showed pH-stimulated DOX release and better antitumor effects. - RGD/TAT dual-targeted MSNs achieved sequential tumor vasculature, cell membrane, and nuclear targeting, enhancing therapeutic efficacy. - Injectable DOX hydrogel reduced tumor volume better than untreated control, hydrogel alone, or intravenous DOX solution in colon and breast tumor models. - Paclitaxel hydrogelator had IC50 25 nM in HeLa cells, comparable to parenteral paclitaxel. - Inhalation siRNA nanoparticles achieved ~65% knockdown of luciferase in A549-Luc orthotopic lung tumors; Akt1 siRNA suppressed Akt1 by ~80% in lungs; salbutamol-targeted chitosan NPs achieved ~40% gene knockdown. - Docetaxel NLC tumor growth inhibition rates: 43%, 63%, and 90% for free drug, NLCs 10 mg/kg, and NLCs 20 mg/kg, respectively, in melanoma-bearing mice.

Interpretation: Carrier-based targeted and localized delivery systems can increase drug accumulation at target sites, enhance treatment efficacy, and reduce adverse side effects. Nanocarriers, supramolecular gels, and live cell-based systems represent promising platforms, but further validation in large animal models is essential for clinical translation.

Limitations: Review article; no primary data. - Many studies remain preclinical; only a limited number of inhalation siRNA reports exist, and they serve mainly as proof-of-concept. - Supramolecular gel-based drug delivery is still in its infancy. - Need for large animal validation before clinical trials. - Challenges remain in biocompatibility, scale-up, regulatory approval, and long-term stability. - Some carriers may induce toxicity or inflammatory responses (e.g., PEI-based nanoparticles caused alveolar wall thickening). - Passive targeting via EPR is ineffective for disseminated metastases; active targeting requires precise ligand selection and may face specificity issues.